UNSPSC 51331704: Sultopride

This classification denotes an antipsychotic agent with the molecular formula C17H26N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AA0G3TW31W, chemically known as o-anisamide, n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)- but generally known as sultopride, which bears US NIH Compound Identifier 5357. European Medicines Agency schedules Sultopride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10763MIG.

UNSPSC 51331704 Sultopride is a Commodity code that captures state and local procurement of pharmaceutical products, specifically opioid-reversal and drug-deactivation medications and systems deployed in community health and public safety contexts. The code sees activity from county health departments and public health authorities purchasing naloxone (Narcan) and associated drug disposal or neutralization systems to support overdose response and substance-abuse harm-reduction initiatives. These procurements typically flow through competitive sealed bidding (IFB) processes and carry standard state and local compliance requirements including drug-free workplace certification, E-Verify employment authorization verification, and specified insurance coverage thresholds.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to the Seminole County Community Health Building in Sanford. The bid deadline was July 26, 2023, with vendors required to submit electronic bids through the county's e-Procurement Portal and include all shipping and delivery costs. The contract structure included a two-year initial term with one-year renewal option and a three-month probationary termination period. The source shows limited recent activity under this code; the single opportunity listed reflects demand from a single Florida county for naloxone and drug-disposal products in a public health procurement context, with no geographic spread or issuing-body diversification evident in the available record.